RAAFEA MALIK: Open Payments
NPI 1467450239 · SAINT PETERS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 33 payments from 8 companies in 2025. Trend: 2023 $230 · 2024 $233 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $139 |
| Vanda Pharmaceuticals Inc. | 4 | $78 |
| E.R. Squibb & Sons, L.L.C. | 3 | $65 |
| ABBVIE INC. | 3 | $59 |
| Lundbeck LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: REXULTI, CAPLYTA, FANAPT, COBENFY, VRAYLAR, ARISTADA, Auvelity.
Industry payments across MO — which companies pay providers there.
